Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
India may issue a warning over cough syrup exported by Marion Biotech linked to a death in Uzbekistan.
Read Full NewsAnemia Correction Before Colorectal Surgery Yields No Postoperative Gains
Mease discussed his hopes for the new approval's impact on the fibromyalgia field.
The rheumatology month in review emphasizes new approvals and the latest comparative research.
Q3 2025 saw several new first targeted therapies for rare and more individualized indications in a number of fields.
Q3 2025 saw a number of exciting approvals and data on promising therapies in development.
Prajapati discussed the impact of the expanded approval of guselkumab to pediatric PsO and psoriatic arthritis.
Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.
1.
U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain
2.
Prostate cancer screening seems to be improved by PSA, biomarker testing, and MRI combined.
3.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
4.
A large study found that monolayers were superior in detecting cancer.
5.
New drug combination shows particularly good results in patients with HPV-negative head and neck cancer
1.
Chondroma: What it is and How it Affects Your Health
2.
The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy
3.
Know About Lymphangioma: Symptoms, Causes, and Treatments
4.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
5.
Breaking Barriers in Cancer Treatment: The Role of Innovative Oncology Drugs
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
3.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge